Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Pérez, José Leonardo"'
Autor:
Varón, Adriana, Pérez, José Leonardo, Torres, Cristina, Pérez, Juan Manuel, Caviedes, José Gabriel, Piñeros, Diego, Mejía, Gilberto, Rivera, Jairo, Murcia, Ciro, Hernández, Geovanny, Garzón, Martin, Beltrán, Oscar
Publikováno v:
In Annals of Hepatology March 2023 28 Supplement 1
Publikováno v:
1. Narváez-Rivera C.A, Cortez-Hernández J.A, González-González J.L, et al. Mexican Consensus on Portal Hypertension R.M. Rev Gastroenterol Mex 2013; 78:92-113 2. De Franchis R; Baveno V Faculty. Expanding consensus in portal hypertension. Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol 2015; 63:743-752. 3. Blasco A, Forns X, Carrion JA, et al. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43:492-499. 4. Kovalak M, Lake J, Mattek N, et al. Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database. Gastrointest Endosc 2007; 65:82-88. 5. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med 2005; 353:2254-2261. 6. Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol 2003; 38:266-272. 7. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017; 65: 1: 310-335. 8. G. D’Amico,R. de Franchis Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology, 2003; 38: 599-612. 9. Abraldes JG, Villanueva C, Banares R, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol, 2008; 48: 229-236. 10. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology, 2007; 46:922-938. 11. Boscha J, Abraldesa JG, Albillos A, Aracil G. Portal hypertension: Recommendations for evaluation and treatment. Gastroenterol Hepatol. 2012; 35:421-50. 12. Reverter E, Tandon P, Augustin S, Turon F, Casu S, Bastiampillai R, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology 2014; 146: 2:412-419. 13. Fortune B, Garcia-Tsao G, Ciarleglio M, Deng Y, Fallon MB, Sigal S, et al. Child-Turcotte-Pugh Class is best at stratifying risk in variceal hemorrhage: analysis of a U.S. multi-center prospective study. J Clin Gastroenterol 2016; 51(5):446-53. 14. Tandon P, Abraldes JG, Keough A, Bastiampillai R, Jayakumar S, Carbonneau M, et al. Risk of bacterial infection in patients with cirrhosis and acute variceal hemorrhage, based on Child-Pugh class, and effects of antibiotics. Clin Gastroenterol Hepatol 2015;13: 6:1189-1196. 15. Abraldes JG, Villanueva C, Bañares R, Aracil C, Catalina MV, Garci JC, et al. Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol; 2008;48: 2:229-236. 16. Martínez JD, Garzón MA, Rey MH, et al. Factores pronósticos asociados con mortalidad en pacientes cirróticos con sangrado varicoso en dos hospitales de Bogotá, Colombia. Rev Col Gastroenterol. 2016; 31: 4: 331-336. 17. Gómez D, Garzón M, Martínez JD, et al. Várices esofágicas: experiencia clínica en un hospital de referencia regional. Rev Col Gastroenterol. 2003; 18: 1. 18. Zuidema, Yeo. Schackelford. Enfermedades del aparato digestivo 5ª Edición. Ed Médica Panamericana. 19. Khanna R, Sarin SK. Non-cirrhotic portal hypertension – Diagnosis and management. J Hepatol. 2014; 60(2):421-41. 20. Cyriac Abby Philips* and Amrish Sahney Oesophageal and gastric varices: historical aspects, classification and grading: everything in one place. Gastroenterol Rep (Oxf). 2016; 4(3): 186–195. 21. Snady H, Feinman L. Prediction of variceal hemorrhage: A prospective study. Am J Gastroentrol 1988;83(5):519–25. 22. Calès P, Zabotto B, Meskens C, et al. Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. Gastroenterology 1990; 98(1):156–62. 23. The Veterans Affairs Cooperative Variceal Sclerotherapy Group. Prophylactic sclerotherapy for esophageal varices in men with alcoholic liver disease. N Engl J Med 1991; 324(25):1779–84. 24. Zoli M, Merkel C, Magalotti D, et al. Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology 1996; 24(5):1047–52. 25. Grace ND. Diagnosis and treatment of gastrointestinal bleeding secondary to portal hypertension. Am J Gastroenterol 1997;92(7):1081–91. 26. Jutabha R, Jensen D, Martin P, et al. A randomized, prospective study of prophylactic rubber band ligation compared to propranolol for prevention of first variceal hemorrhage in cirrhotics with large esophageal varices. Gastrointest Endosc 2001; 53:568. 27. Sarin SK, Lahoti D, Saxena SP, et al. Prevalence, classification and natural history of gastric varices: a long-term follow-up study in 568 portal hypertension patients. Hepatology 1992; 16(6):1343–1349. 28. Arakawa M, Masuzaki T, Okuda K. Pathomorphology of esophageal and gastric varices. Semin Liver Dis 2002;22(1):73–81. 29. Iwase H, Maeda O, Shimada M, et al. Endoscopic ablation with cyanoacrylate glue for isolated gastric variceal bleeding. Gastroint Endosc 2001; 53(6):585–59 30. Kovalak M, Lake J, Mattek N, et al. Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database. 65 (Gastrointest Endosc 2007), pp. 828. 31. Lujano S, Valdés L, Corral M, et al. Factores asociados a la presencia de várices en pacientes cirróticos envíados a endoscopia de tamizaje, 21 (Endoscopia 2009), pp. 38-4. 32. Negreanu L. Busegeanu C. Trandafir D. Dragomir P. Portal hypertensive gastropathy. 43 (Rom J Intern Med 2005), pp. 3-8. 33. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis., 362 (N Engl J Med 2010), pp. 823-32 34. Garcia-Tsao G, Lim J, et al. Management and treatment of patients with cirrhosis and portal hypertension: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program., 104 (Am J Gastroenterol 2009), pp. 1802-1829.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: La hipertensión portal se define como el aumento en el gradiente de presión porto sistémica > a 5 mmHg, es la anomalía hemodinámica asociada a complicaciones más graves en cirrosis. La hemorragia varicosa es una emergencia médic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::246011599bfcb68db9ff43062f77c636
http://repository.urosario.edu.co/handle/10336/19125
http://repository.urosario.edu.co/handle/10336/19125
Publikováno v:
Peterson Re. Adrenocortical steroid metabolism and adrenal cortical function in liver disease. J Clin Invest. 1960;39(2):320-331. doi:10.1172/JCI104043
Marik PE, Gayowski T, Starzl TE; Hepatic Cortisol Research and Adrenal Pathophysiology Study Group. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med. 2005 Jun;33(6):1254-9. doi: 10.1097/01.ccm.0000164541.12106.57.
Trifan A, Chiriac S, Stanciu C. Update on adrenal insufficiency in patients with liver cirrhosis. World J Gastroenterol. 2013 Jan 28;19(4):445-56. doi: 10.3748/wjg.v19.i4.445. PMID: 23382623; PMCID: PMC3558568
Kim G, Huh JH, Lee KJ, Kim MY, Shim KY, Baik SK. Relative Adrenal Insufficiency in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2017 Apr;62(4):1067-1079. doi: 10.1007/s10620-017-4471-8. Epub 2017 Feb 7. PMID: 28176190.
Spadaro L, Noto D, Privitera G, et al. Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. Scand J Gastroenterol. 2015;50(3):347-354. doi:10.3109/00365521.2014.985707
Marik PE. Adrenal-exhaustion syndrome in patients with liver disease. Intensive Care Med. 2006;32(2):275-280. doi:10.1007/s00134-005-0005-5
Triantos CK, Marzigie M, Fede G, Michalaki M, Giannakopoulou D, Thomopoulos K, Garcovich M, Kalafateli M, Chronis A, Kyriazopoulou V, Jelastopoulou E, Nikolopoulou V, O'Beirne J, Burroughs AK. Critical illness-related corticosteroid insufficiency in patients with cirrhosis and variceal bleeding. Clin Gastroenterol Hepatol. 2011 Jul;9(7):595-601. doi: 10.1016/j.cgh.2011.03.033. Epub 2011 Apr 8. PMID: 21545846.
Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, Thomas M, Bouloux PM, Burroughs AK, Purrello F. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology. 2012 Apr;55(4):1282-91. doi: 10.1002/hep.25573. PMID: 22234976.
Thevenot T, Borot S, Remy-Martin A, Sapin R, Cervoni JP, Richou C, Vanlemmens C, Cleau D, Muel E, Minello A, Tirziu S, Penfornis A, Di Martino V, Monnet E. Assessment of adrenal function in cirrhotic patients using concentration of serumfree and salivary cortisol. Liver Int. 2011 Mar;31(3):425-33. doi: 10.1111/j.1478-3231.2010.02431.x. Epub 2011 Jan 13. PMID: 21281437
Tan T, Chang L, Woodward A, McWhinney B, Galligan J, Macdonald GA, Cohen J, Venkatesh B. Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease. J Hepatol. 2010 Nov;53(5):841-8. doi: 10.1016/j.jhep.2010.05.020. Epub 2010 Jul 17.
Fede G, Spadaro L, Tomaselli T, Privitera G, Scicali R, Vasianopoulou P, Thalassinos E, Martin N, Thomas M, Purrello F, Burroughs AK. Comparison of total cortisol, free cortisol, and surrogate markers of free cortisol in diagnosis of adrenal insufficiency in patients with stable cirrhosis. Clin Gastroenterol Hepatol. 2014 Mar;12(3):504-12.e8; quiz e23-4. doi: 10.1016/j.cgh.2013.08.028. Epub 2013 Aug 24. PMID: 23978347.
Galbois A, Rudler M, Massard J, Fulla Y, Bennani A, Bonnefont-Rousselot D, Thibault V, Reignier S, Bourrier A, Poynard T, Thabut D. Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol. 2010 Jun;52(6):839-45. doi: 10.1016/j.jhep.2010.01.026. Epub 2010 Mar 15. PMID: 20385427.
Acevedo J, Fernández J, Prado V, Silva A, Castro M, Pavesi M, Roca D, Jimenez W, Ginès P, Arroyo V. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology. 2013 Nov;58(5):1757-65. doi: 10.1002/hep.26535. Epub 2013 Aug 7. Erratum in: Hepatology. 2015 Jun;61(6):2121. PMID: 23728792.
Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, Knawy BA, Hajeer AH, Tamimi W, Cherfan A. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ. 2010 Dec 14;182(18):1971-7. doi: 10.1503/cmaj.090707. Epub 2010 Nov 8. PMID: 21059778; PMCID: PMC3001503.
Fernández J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, Lacy AM, Ginès P, Arroyo V. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology. 2006 Nov;44(5):1288-95. doi: 10.1002/hep.21352. PMID: 17058239.
Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int. 2003 Apr;23(2):71-7. doi: 10.1034/j.1600-0676.2003.00813.x. PMID: 12654129
Vu T, Vallabh M, Laine G. Adrenal Insufficiency and Response to Stress Dose Hydrocortisone in Patients With Cirrhosis and Vasopressor Dependency Using Cirrhosis-Specific Cortisol Thresholds [published online ahead of print, 2020 Jan 12]. Ann Pharmacother. 2020;1060028019900266. doi:10.1177/1060028019900266
Graupera I, Pavel O, Hernandez-Gea V, Ardevol A, Webb S, Urgell E, Colomo A, Llaó J, Concepción M, Villanueva C. Relative adrenal insufficiency in severe acute variceal and non-variceal bleeding: influence on outcomes. Liver Int. 2015 Aug;35(8):1964-73. doi: 10.1111/liv.12788. Epub 2015 Feb 10. PMID: 25644679.
Tsai MH, Huang HC, Peng YS, Chen YC, Tian YC, Yang CW, Lien JM, Fang JT, Wu CS, Lee FY. Critical illness-related corticosteroid insufficiency in cirrhotic patients with acute gastroesophageal variceal bleeding: risk factors and association with outcome*. Crit Care Med. 2014 Dec;42(12):2546-55. doi: 10.1097/CCM.0000000000000544. PMID: 25083978.
Piano S, Favaretto E, Tonon M, Antonelli G, Brocca A, Sticca A, Mareso S, Gringeri E, Scaroni C, Plebani M, Russo FP, Burra P, Cillo U, Angeli P. Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2020 May;18(5):1188-1196.e3. doi: 10.1016/j.cgh.2019.09.035. Epub 2019 Oct 4. PMID: 31589973.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Marik PE, Gayowski T, Starzl TE; Hepatic Cortisol Research and Adrenal Pathophysiology Study Group. The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med. 2005 Jun;33(6):1254-9. doi: 10.1097/01.ccm.0000164541.12106.57.
Trifan A, Chiriac S, Stanciu C. Update on adrenal insufficiency in patients with liver cirrhosis. World J Gastroenterol. 2013 Jan 28;19(4):445-56. doi: 10.3748/wjg.v19.i4.445. PMID: 23382623; PMCID: PMC3558568
Kim G, Huh JH, Lee KJ, Kim MY, Shim KY, Baik SK. Relative Adrenal Insufficiency in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2017 Apr;62(4):1067-1079. doi: 10.1007/s10620-017-4471-8. Epub 2017 Feb 7. PMID: 28176190.
Spadaro L, Noto D, Privitera G, et al. Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. Scand J Gastroenterol. 2015;50(3):347-354. doi:10.3109/00365521.2014.985707
Marik PE. Adrenal-exhaustion syndrome in patients with liver disease. Intensive Care Med. 2006;32(2):275-280. doi:10.1007/s00134-005-0005-5
Triantos CK, Marzigie M, Fede G, Michalaki M, Giannakopoulou D, Thomopoulos K, Garcovich M, Kalafateli M, Chronis A, Kyriazopoulou V, Jelastopoulou E, Nikolopoulou V, O'Beirne J, Burroughs AK. Critical illness-related corticosteroid insufficiency in patients with cirrhosis and variceal bleeding. Clin Gastroenterol Hepatol. 2011 Jul;9(7):595-601. doi: 10.1016/j.cgh.2011.03.033. Epub 2011 Apr 8. PMID: 21545846.
Fede G, Spadaro L, Tomaselli T, Privitera G, Germani G, Tsochatzis E, Thomas M, Bouloux PM, Burroughs AK, Purrello F. Adrenocortical dysfunction in liver disease: a systematic review. Hepatology. 2012 Apr;55(4):1282-91. doi: 10.1002/hep.25573. PMID: 22234976.
Thevenot T, Borot S, Remy-Martin A, Sapin R, Cervoni JP, Richou C, Vanlemmens C, Cleau D, Muel E, Minello A, Tirziu S, Penfornis A, Di Martino V, Monnet E. Assessment of adrenal function in cirrhotic patients using concentration of serumfree and salivary cortisol. Liver Int. 2011 Mar;31(3):425-33. doi: 10.1111/j.1478-3231.2010.02431.x. Epub 2011 Jan 13. PMID: 21281437
Tan T, Chang L, Woodward A, McWhinney B, Galligan J, Macdonald GA, Cohen J, Venkatesh B. Characterising adrenal function using directly measured plasma free cortisol in stable severe liver disease. J Hepatol. 2010 Nov;53(5):841-8. doi: 10.1016/j.jhep.2010.05.020. Epub 2010 Jul 17.
Fede G, Spadaro L, Tomaselli T, Privitera G, Scicali R, Vasianopoulou P, Thalassinos E, Martin N, Thomas M, Purrello F, Burroughs AK. Comparison of total cortisol, free cortisol, and surrogate markers of free cortisol in diagnosis of adrenal insufficiency in patients with stable cirrhosis. Clin Gastroenterol Hepatol. 2014 Mar;12(3):504-12.e8; quiz e23-4. doi: 10.1016/j.cgh.2013.08.028. Epub 2013 Aug 24. PMID: 23978347.
Galbois A, Rudler M, Massard J, Fulla Y, Bennani A, Bonnefont-Rousselot D, Thibault V, Reignier S, Bourrier A, Poynard T, Thabut D. Assessment of adrenal function in cirrhotic patients: salivary cortisol should be preferred. J Hepatol. 2010 Jun;52(6):839-45. doi: 10.1016/j.jhep.2010.01.026. Epub 2010 Mar 15. PMID: 20385427.
Acevedo J, Fernández J, Prado V, Silva A, Castro M, Pavesi M, Roca D, Jimenez W, Ginès P, Arroyo V. Relative adrenal insufficiency in decompensated cirrhosis: Relationship to short-term risk of severe sepsis, hepatorenal syndrome, and death. Hepatology. 2013 Nov;58(5):1757-65. doi: 10.1002/hep.26535. Epub 2013 Aug 7. Erratum in: Hepatology. 2015 Jun;61(6):2121. PMID: 23728792.
Arabi YM, Aljumah A, Dabbagh O, Tamim HM, Rishu AH, Al-Abdulkareem A, Knawy BA, Hajeer AH, Tamimi W, Cherfan A. Low-dose hydrocortisone in patients with cirrhosis and septic shock: a randomized controlled trial. CMAJ. 2010 Dec 14;182(18):1971-7. doi: 10.1503/cmaj.090707. Epub 2010 Nov 8. PMID: 21059778; PMCID: PMC3001503.
Fernández J, Escorsell A, Zabalza M, Felipe V, Navasa M, Mas A, Lacy AM, Ginès P, Arroyo V. Adrenal insufficiency in patients with cirrhosis and septic shock: Effect of treatment with hydrocortisone on survival. Hepatology. 2006 Nov;44(5):1288-95. doi: 10.1002/hep.21352. PMID: 17058239.
Harry R, Auzinger G, Wendon J. The effects of supraphysiological doses of corticosteroids in hypotensive liver failure. Liver Int. 2003 Apr;23(2):71-7. doi: 10.1034/j.1600-0676.2003.00813.x. PMID: 12654129
Vu T, Vallabh M, Laine G. Adrenal Insufficiency and Response to Stress Dose Hydrocortisone in Patients With Cirrhosis and Vasopressor Dependency Using Cirrhosis-Specific Cortisol Thresholds [published online ahead of print, 2020 Jan 12]. Ann Pharmacother. 2020;1060028019900266. doi:10.1177/1060028019900266
Graupera I, Pavel O, Hernandez-Gea V, Ardevol A, Webb S, Urgell E, Colomo A, Llaó J, Concepción M, Villanueva C. Relative adrenal insufficiency in severe acute variceal and non-variceal bleeding: influence on outcomes. Liver Int. 2015 Aug;35(8):1964-73. doi: 10.1111/liv.12788. Epub 2015 Feb 10. PMID: 25644679.
Tsai MH, Huang HC, Peng YS, Chen YC, Tian YC, Yang CW, Lien JM, Fang JT, Wu CS, Lee FY. Critical illness-related corticosteroid insufficiency in cirrhotic patients with acute gastroesophageal variceal bleeding: risk factors and association with outcome*. Crit Care Med. 2014 Dec;42(12):2546-55. doi: 10.1097/CCM.0000000000000544. PMID: 25083978.
Piano S, Favaretto E, Tonon M, Antonelli G, Brocca A, Sticca A, Mareso S, Gringeri E, Scaroni C, Plebani M, Russo FP, Burra P, Cillo U, Angeli P. Including Relative Adrenal Insufficiency in Definition and Classification of Acute-on-Chronic Liver Failure. Clin Gastroenterol Hepatol. 2020 May;18(5):1188-1196.e3. doi: 10.1016/j.cgh.2019.09.035. Epub 2019 Oct 4. PMID: 31589973.
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: El síndrome hepatoadrenal es frecuente en los pacientes con cirrosis descompensada y críticamente enfermos. Buscamos identificar la evidencia sobre el impacto del síndrome hepatoadrenal en el desenlace de mortalidad de pacientes con
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46eade8b2eefd891fe64a888ae8b1ad2
https://repository.urosario.edu.co/handle/10336/33715
https://repository.urosario.edu.co/handle/10336/33715
Autor:
Díaz Nassif, Gustavo Andrés
Publikováno v:
1. Estadística institucional Fundación Cardioinfantil – Instituto de Cardiología. Servicio de Epidemiología – 2013.
2. Gupta k, Bhadelia N. Management of Urinary Tract Infections from Multidrug-Resistant Organisms. Infect Dis Clin N Am. 2014;28:49-59.
3. Wang P, Hu F, Xiong Z, Ye X, Zhy D, Wang YF, et al. Susceptibility of Extended-Spectrum-b-Lactamase-Producing Enterobacteriaceae According to the New CLSI breakpoints. J Clin Microbiol. 2011;49(9):3127-3131.
4. Aboumarzouk OM. Extended spectrum beta-lactamase urinary tract infections. Urol Ann. 2014;6(2):114-115.
5. Ranjan KP, Ranjan N. Complicated urinary tract infection caused by extended spectrum b-lactamase-producing Escherichia coli. Urol Ann;2014:6(2):112-113.
6. Taneja N, Rao P, Arora J, Dogra A. Ocurrence of ESBL and Amp-C beta-lactamases and susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res. 2008;127-85-8.
7. Foxman B. Urinary Tract Infections Syndromes Occurrence, Recurrence, Bacteriology, Risk Factors, and Disease Burden. Infect Dis Clin N Am. 2014;28:1-13.
8. Suárez C, Gudiol F. Antibióticos betalactámicos. Enferm Infecc Microbiol Clin. 2009;27(2):116-129.
9. Fraimow H, Tsigrelis C. Antimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and management of Specific Resistant Pathogens. Crit Care Clin. 2011;27:163-205.
11. Cercenado E. Impacto pronóstico de las betalactamasas de espectro extendido. Rev Clin Esp. 2011;211:139-4.
12. Pujol M, Peña C. El significado clínico de las betalactamasas de espectro extendido. Enferm Infecc Microbiol Clin;21(2):69-71.
13. Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended Spectrum Beta-lactamases: Definition, Classification and Epidemiology. Curr Issues Mol Biol. 2014;17:11-22.
14. Bush K, Jacoby GA. Updated Functional Classification of b-lactamases. Antimicrob Agents Chemother. 2010;54(3):969-976.
15. Seral García C, Pardos de la Gándara M, Castillo García FJ. Betalactamasas de espectro extendido en enterobacterias distintas de Escherichia coli y Klebsiella. Enferm Infecc Microbiol Clin. 2010;28(supl 1):12-18.
16. M. Raynor. Urinary infections in men. Med Clin N Am.2011;95:43–54
17. Takhar S, Moran G. Diagnosis and management of urinary tract infections in the emergency department and outpatient setting. Infect Dis Clin N Am. 2014; 28:33-48.
18. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625.
19. Horan T, Andrus M, Dudeck M. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-32.
20. Nicolle L. Unriary tract infections in special populations: diabetes, renal transplant, HIV infection and spinal cord injury. Infect Dis Clin N Am 28 (2014) 91-104.
21. Klavs I, Bufon Luznik T, Skerl M, et al. Prevalence of and risk factors for hospital-acquired infections in Slovenia-results of the first national survey.J Hosp Infect 2003; 54:. 149-157
22. Bagshaw, Sean M; Laupland, Kevin B Epidemiology of intensive care unit-acquired urinary tract infectionsBagshaw, Sean M
23. Garibaldi R, Mooney B, Epstein B, Britt M. An evaluation of daily bacteriologic monitoring to identify preventable episodes of catheter-associated urinary tract infection. Infect Control de 1982; 3:. 466-470
24. Leona M, J Albanese, Garnier F, et al. Los factores deRisk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit. Intensive Care Med 2003; 29:. 1077-1080
García-Tello A, Gimbernat H, Redondo C, Arana DM, Cacho J, Angulo JC. Extended-spectrum beta-lactamases in urinary tract infections caused by Enterobacteria: understanding and guidelines for action. Actas Urol españolas. 2014 Dec;38(10):678–84.
26. Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis. 2016 Jul 11
27. Melaku S, Kibret M, Abera B, Gebre-Sellassie S. Antibiogram of nosocomial urinary tract infections in Felege Hiwot referral hospital, Ethiopia. Afr Health Sci. 2012 Jun;12(2):134–9.
28. Tiwari MM, Charlton ME, Anderson JR, Hermsen ED, Rupp ME. Inappropriate use of urinary catheters: a prospective observational study. Am J Infect Control. 2012 Feb;40(1):51–4.
29. Someshwaran R, Prakash KG, Deshpande SA, Aravazhi AN. Adherence to Hospital Antibiotic Policy for Treatment of Escherichia coli ESBL in Urine. J Clin Diagn Res 2016 Mar;10(3):DC01–4.
30. Rosenthal VD, Dwivedy A, Calderón MER, Esen S, Hernández HT, Abouqal R, et al. Time-dependent analysis of length of stay and mortality due to urinary tract infections in ten developing countries: INICC findings. J Infect. 2011 Feb;62(2):136–41
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
2. Gupta k, Bhadelia N. Management of Urinary Tract Infections from Multidrug-Resistant Organisms. Infect Dis Clin N Am. 2014;28:49-59.
3. Wang P, Hu F, Xiong Z, Ye X, Zhy D, Wang YF, et al. Susceptibility of Extended-Spectrum-b-Lactamase-Producing Enterobacteriaceae According to the New CLSI breakpoints. J Clin Microbiol. 2011;49(9):3127-3131.
4. Aboumarzouk OM. Extended spectrum beta-lactamase urinary tract infections. Urol Ann. 2014;6(2):114-115.
5. Ranjan KP, Ranjan N. Complicated urinary tract infection caused by extended spectrum b-lactamase-producing Escherichia coli. Urol Ann;2014:6(2):112-113.
6. Taneja N, Rao P, Arora J, Dogra A. Ocurrence of ESBL and Amp-C beta-lactamases and susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res. 2008;127-85-8.
7. Foxman B. Urinary Tract Infections Syndromes Occurrence, Recurrence, Bacteriology, Risk Factors, and Disease Burden. Infect Dis Clin N Am. 2014;28:1-13.
8. Suárez C, Gudiol F. Antibióticos betalactámicos. Enferm Infecc Microbiol Clin. 2009;27(2):116-129.
9. Fraimow H, Tsigrelis C. Antimicrobial Resistance in the Intensive Care Unit: Mechanisms, Epidemiology, and management of Specific Resistant Pathogens. Crit Care Clin. 2011;27:163-205.
11. Cercenado E. Impacto pronóstico de las betalactamasas de espectro extendido. Rev Clin Esp. 2011;211:139-4.
12. Pujol M, Peña C. El significado clínico de las betalactamasas de espectro extendido. Enferm Infecc Microbiol Clin;21(2):69-71.
13. Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended Spectrum Beta-lactamases: Definition, Classification and Epidemiology. Curr Issues Mol Biol. 2014;17:11-22.
14. Bush K, Jacoby GA. Updated Functional Classification of b-lactamases. Antimicrob Agents Chemother. 2010;54(3):969-976.
15. Seral García C, Pardos de la Gándara M, Castillo García FJ. Betalactamasas de espectro extendido en enterobacterias distintas de Escherichia coli y Klebsiella. Enferm Infecc Microbiol Clin. 2010;28(supl 1):12-18.
16. M. Raynor. Urinary infections in men. Med Clin N Am.2011;95:43–54
17. Takhar S, Moran G. Diagnosis and management of urinary tract infections in the emergency department and outpatient setting. Infect Dis Clin N Am. 2014; 28:33-48.
18. Hooton TM, Bradley SF, Cardenas DD, Colgan R, Geerlings SE, Rice JC, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(5):625.
19. Horan T, Andrus M, Dudeck M. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36:309-32.
20. Nicolle L. Unriary tract infections in special populations: diabetes, renal transplant, HIV infection and spinal cord injury. Infect Dis Clin N Am 28 (2014) 91-104.
21. Klavs I, Bufon Luznik T, Skerl M, et al. Prevalence of and risk factors for hospital-acquired infections in Slovenia-results of the first national survey.J Hosp Infect 2003; 54:. 149-157
22. Bagshaw, Sean M; Laupland, Kevin B Epidemiology of intensive care unit-acquired urinary tract infectionsBagshaw, Sean M
23. Garibaldi R, Mooney B, Epstein B, Britt M. An evaluation of daily bacteriologic monitoring to identify preventable episodes of catheter-associated urinary tract infection. Infect Control de 1982; 3:. 466-470
24. Leona M, J Albanese, Garnier F, et al. Los factores deRisk factors of nosocomial catheter-associated urinary tract infection in a polyvalent intensive care unit. Intensive Care Med 2003; 29:. 1077-1080
García-Tello A, Gimbernat H, Redondo C, Arana DM, Cacho J, Angulo JC. Extended-spectrum beta-lactamases in urinary tract infections caused by Enterobacteria: understanding and guidelines for action. Actas Urol españolas. 2014 Dec;38(10):678–84.
26. Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis. 2016 Jul 11
27. Melaku S, Kibret M, Abera B, Gebre-Sellassie S. Antibiogram of nosocomial urinary tract infections in Felege Hiwot referral hospital, Ethiopia. Afr Health Sci. 2012 Jun;12(2):134–9.
28. Tiwari MM, Charlton ME, Anderson JR, Hermsen ED, Rupp ME. Inappropriate use of urinary catheters: a prospective observational study. Am J Infect Control. 2012 Feb;40(1):51–4.
29. Someshwaran R, Prakash KG, Deshpande SA, Aravazhi AN. Adherence to Hospital Antibiotic Policy for Treatment of Escherichia coli ESBL in Urine. J Clin Diagn Res 2016 Mar;10(3):DC01–4.
30. Rosenthal VD, Dwivedy A, Calderón MER, Esen S, Hernández HT, Abouqal R, et al. Time-dependent analysis of length of stay and mortality due to urinary tract infections in ten developing countries: INICC findings. J Infect. 2011 Feb;62(2):136–41
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
Introducción: La IVU es muy frecuenten en la (FCI - IC), Alrededor el 60% de los pacientes con diagnóstico de IVU nosocomial corresponden a gérmenes resistente, Desde el año 2010 el CLSI disminuyó los puntos de corte de sensibilidad en las enter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::677936902a24ee8a2c5f173b6d15b834